Open AccessSecukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5
Author(s) -
Feng Huang,
Fei Sun,
Wei Wan,
Lele Wu,
Lei Dong,
Xiao Zhang,
So Yeon Kim,
Raj Sengupta,
Ladislav Šenolt,
Yi Wang,
Hao Qiu,
Brian Porter,
Sibylle Haemmerle
Publication year - 2020
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001099
Subject(s) - secukinumab , medicine , ankylosing spondylitis , placebo , clinical endpoint , population , randomization , randomized controlled trial , psoriatic arthritis , disease , alternative medicine , environmental health , pathology
Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis (AS) through 5 years in pivotal Phase III studies. Here, we present efficacy and safety results (52-week) of secukinumab in patients with AS from the MEASURE 5 study.